Rewiring Recovery: Psychedelic-Assisted Therapy (PAT) in Practice

In this episode, we explore the evolving evidence base and clinical considerations around psychedelic‑assisted therapies in Australia. Belmont Private Hospital Psychiatrists Dr Lana Fernandes and Dr Scott Newman join GP host Dr Peta‑Ann Teague to discuss how substances such as psilocybin, MDMA and ketamine are being studied and, in limited circumstances, clinically applied within a regulated framework. The conversation focuses on treatment‑resistant depression and post‑traumatic stress disorder, outlining current diagnostic definitions, patient selection considerations, and how psychedelic‑assisted therapy differs from standard pharmacological treatment. The guests discuss assessment requirements, safety considerations, medical and psychiatric exclusions, and the importance of intensive psychological support before, during and after treatment. This episode is intended for health professionals and provides general educational information only. It does not constitute medical advice, does not promote specific treatments, and does not replace individual clinical assessment or referral pathways. Psychedelic‑assisted therapies are highly regulated in Australia and are only appropriate for select patients following specialist assessment. Learning outcomes Apply current clinical definitions of treatment‑resistant depression and post‑traumatic stress disorder when assessing patients in general practice. Identify patient factors, contraindications and red flags relevant to considering referral for psychedelic‑assisted therapy. Describe the GP’s role within a psychiatrist‑led, regulated model of psychedelic‑assisted therapy, including referral pathways and shared care. Evaluate the current evidence base, limitations and uncertainties of psychedelic‑assisted therapies to support informed, patient‑centred discussions.